How to Get Dayvigo (Lemborexant) in Colorado

What Is Lemborexant and Why Consider It for Insomnia?

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting neuropeptides orexin-A and orexin-B, reducing the drive to stay awake rather than sedating the brain broadly [1]. The FDA approved Dayvigo in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance in adults [2].

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared to placebo at one month. The 10 mg dose cut sleep-onset latency by a mean of 10.5 minutes more than placebo (P<0.001) [3]. A second study, SUNRISE-2, showed that improvements in subjective sleep onset and maintenance persisted over 12 months of nightly use without evidence of rebound insomnia upon discontinuation [4]. These findings are part of why the American Academy of Sleep Medicine (AASM) conditionally recommends DORAs for sleep-maintenance insomnia in adults [5].

Unlike older hypnotics such as zolpidem (Ambien), lemborexant carries a lower risk of next-morning residual sedation at the 5 mg dose, an important consideration for patients who drive or operate equipment early in the day [2]. Colorado providers increasingly prescribe DORAs as a first-line pharmacotherapy when cognitive behavioral therapy for insomnia (CBT-I) alone has not resolved symptoms.

Colorado Telehealth Rules for Schedule IV Prescriptions

Colorado law allows telehealth prescribing of Schedule IV controlled substances, which includes Dayvigo. A provider does not need to see the patient in person first, as long as the encounter meets the Colorado Medical Board's standard-of-care requirements for a synchronous audio-video visit [6].

This means a Colorado resident can consult a licensed physician, nurse practitioner, or physician assistant through a HIPAA-compliant video platform and receive a Dayvigo prescription electronically. The prescriber must hold an active Colorado medical license (or be authorized through the Interstate Medical Licensure Compact) and maintain a valid DEA registration. Colorado joined the Interstate Medical Licensure Compact in 2017, which broadens the pool of eligible out-of-state physicians [6].

For patients in rural areas of the state, from the Western Slope to the Eastern Plains, telehealth removes the barrier of driving hours to reach a sleep specialist. The Colorado Department of Regulatory Agencies (DORA, coincidentally) confirmed in 2023 that telehealth parity requirements extend to behavioral health and sleep medicine visits.

Who Can Prescribe Dayvigo in Colorado?

Any licensed prescriber with Schedule IV authority can write a Dayvigo prescription in Colorado. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Colorado grants NPs full practice authority after 3,000 hours of supervised practice, meaning many NPs prescribe independently without physician oversight [7].

Sleep medicine specialists typically manage complex or treatment-resistant insomnia, but a primary care provider can prescribe Dayvigo after confirming the diagnosis. The AASM recommends that clinicians screen for obstructive sleep apnea, restless legs syndrome, and circadian rhythm disorders before starting any hypnotic [5]. A sleep diary spanning at least two weeks, combined with a validated screening tool like the Insomnia Severity Index (ISI), generally satisfies documentation requirements.

PAs in Colorado practice under a collaborative agreement but can prescribe controlled substances independently once the agreement is established. There is no state-mandated requirement for a sleep study before prescribing Dayvigo, though some insurers request one as part of prior authorization.

What Labs or Evaluations Are Needed Before Starting Dayvigo?

No specific laboratory tests are required by the FDA label before initiating lemborexant [2]. The prescribing information recommends a clinical assessment for narcolepsy and cataplexy (since blocking orexin receptors could theoretically worsen narcolepsy-spectrum conditions) and screening for moderate-to-severe hepatic impairment, which increases drug exposure.

In practice, a Colorado prescriber will typically review the following before writing the prescription:

• A sleep history covering symptom duration, pattern (onset vs. maintenance vs. both), and prior treatments tried
• Current medications, especially other CNS depressants, CYP3A4 inhibitors, and alcohol use
• A screening questionnaire such as the STOP-BANG for obstructive sleep apnea risk
• Hepatic function if the patient has known liver disease or risk factors for MASLD

Dr. Andrew Krystal, a sleep researcher at UCSF and co-investigator on the SUNRISE trials, noted in a 2020 commentary: "The orexin antagonist mechanism offers a pharmacologically distinct option from GABA-A modulators, which may be particularly relevant for patients who have experienced tolerance or adverse effects with benzodiazepine-receptor agonists" [8].

The lack of mandatory labs makes telehealth initiation straightforward. A provider can complete the assessment, prescribe electronically, and have the patient pick up the medication at a Colorado pharmacy within days.

Insurance Coverage and Prior Authorization in Colorado

Commercial insurance plans in Colorado vary in their formulary placement of Dayvigo. Most plans that cover it place the drug on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with monthly copays typically ranging from $30 to $75 with prior authorization approved [9].

Colorado Medicaid (Health First Colorado) does not cover Dayvigo for insomnia. The state Medicaid formulary limits coverage to a narrow type 2 diabetes indication, which is not an FDA-approved use of lemborexant. Patients on Medicaid who need a DORA may explore manufacturer savings programs or switch to suvorexant (Belsomra), which has different formulary positioning depending on the managed care organization.

For commercial plans requiring prior authorization, the documentation package usually includes:

• Confirmed diagnosis of insomnia disorder (ICD-10 G47.00 or G47.01)
• Documentation that CBT-I was offered or attempted (many plans require at least one prior therapy)
• Failure of, intolerance to, or contraindication for at least one generic hypnotic (e.g., zolpidem, eszopiclone, or trazodone)
• A clinical rationale explaining why lemborexant is medically necessary

Processing times range from 48 hours to 14 business days. If the plan denies coverage, Colorado patients may file an external appeal through the Colorado Division of Insurance, which is independent of the insurer [10].

Eisai offers a copay savings card for commercially insured patients that can reduce the out-of-pocket cost to as low as $0 per fill for eligible individuals. Uninsured patients can check the Eisai Patient Assistance Program for potential free or reduced-cost supply.

503A Compounding Pharmacies in Colorado

Colorado licenses 503A compounding pharmacies under the State Board of Pharmacy, and these pharmacies may compound lemborexant preparations when a valid patient-specific prescription exists [11]. A 503A pharmacy compounds medications on an individual basis, not in bulk, and the compounded product must be dispensed directly to the patient or the prescriber's office.

This pathway is most useful when a patient needs a dose form not commercially available (for example, a liquid suspension for patients who cannot swallow tablets) or when the commercial product is on backorder. The compounding pharmacy must source pharmaceutical-grade lemborexant powder from an FDA-registered supplier.

Colorado's 503A pharmacies can ship within the state. Some pharmacies with NABP-accredited mail-order licenses may ship to patients in other states if allowed by the receiving state's laws. For most Colorado patients, the simpler route is filling the branded Dayvigo tablet at a retail or mail-order pharmacy.

How Long Until You Receive Dayvigo in Colorado?

The timeline from initial consultation to medication in hand depends on several factors. A straightforward path looks like this:

• Day 1: Telehealth or in-person visit with a licensed provider. E-prescription sent to pharmacy.
• Days 2 to 3: Pharmacy receives and processes the prescription. If no prior authorization is needed, the medication is available for pickup or shipped.
• Days 3 to 7: If prior authorization is required, the prescriber's office submits documentation. Most commercial plans respond within 72 hours.
• Days 7 to 10: If the initial PA is denied and a peer-to-peer review is requested, expect an additional 3 to 5 business days.

For patients using a telehealth platform with an integrated pharmacy, the prescription can sometimes be filled and shipped within 48 hours of the visit (assuming no PA requirement). Colorado mail-order pharmacies typically deliver within 2 to 5 business days via USPS or courier.

Dr. Nathaniel Watson, former president of the AASM, has stated: "Access to evidence-based insomnia treatments should not be limited by geography. Telehealth paired with mail-order pharmacy services can meaningfully reduce the time from diagnosis to treatment" [12].

Transferring a Dayvigo Prescription to Colorado

Patients relocating to Colorado can transfer an existing Dayvigo prescription from another state, provided both pharmacies agree and the transfer complies with DEA regulations for Schedule IV substances. Under federal law, a Schedule IV prescription may be transferred between pharmacies one time only, unless both pharmacies share a real-time electronic database [13].

The practical steps are:

1. Contact the new Colorado pharmacy and provide the original pharmacy's name, phone number, and prescription number.
2. The receiving pharmacist will call the originating pharmacy to initiate the transfer.
3. Both pharmacists document the transfer, including remaining refills.

If the prescription has no remaining refills, the patient will need a new prescription from a Colorado-licensed provider. A telehealth visit is the fastest way to establish care. Many patients set up a telehealth appointment before they move so the new prescription is ready on arrival.

Dayvigo Dosing and Safety Considerations

The recommended starting dose is 5 mg taken orally within 5 minutes of bedtime, with at least 7 hours of sleep opportunity remaining [2]. The dose may be increased to 10 mg if the 5 mg dose is well tolerated but insufficiently effective. The maximum recommended dose is 10 mg per night.

Common adverse effects reported in clinical trials include somnolence (reported in 10% of patients on 10 mg vs. 1% on placebo), headache, and abnormal dreams [3]. Sleep paralysis and hypnagogic hallucinations occurred at low rates (approximately 1% to 2%) but should be discussed with patients before initiation.

In SUNRISE-1, discontinuation rates due to adverse events were 3.3% for lemborexant 5 mg, 4.5% for 10 mg, and 3.1% for placebo, indicating that most patients tolerated the drug well enough to continue [3]. No next-morning driving impairment was detected at the 5 mg dose in a driving-simulation study, though the 10 mg dose showed mild impairment in the first few hours after waking [2].

Patients should avoid taking Dayvigo with alcohol, other CNS depressants, or strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin). Moderate CYP3A4 inhibitors such as fluconazole require a dose reduction to 5 mg maximum [2].

Comparing Dayvigo to Other Insomnia Medications Available in Colorado

Colorado patients have access to several insomnia pharmacotherapies. The choice between them depends on symptom pattern, comorbidities, and insurance coverage.

Suvorexant (Belsomra) is the other FDA-approved DORA. In a head-to-head analysis, lemborexant 10 mg showed numerically greater reductions in wake after sleep onset (WASO) than suvorexant 20 mg in SUNRISE-1, though direct comparison trials between the two drugs have not been published [3]. Suvorexant is available in generic form as of 2023, which can make it a more cost-effective first step.

Zolpidem (Ambien) remains the most widely prescribed sleep aid in Colorado and nationally. It works on GABA-A receptors and is effective for sleep-onset insomnia but carries risks of complex sleep behaviors (sleepwalking, sleep-driving), tolerance, and next-day impairment, particularly in women and older adults [14]. The FDA mandated a boxed warning for zolpidem and similar drugs in 2019.

Trazodone, an off-label sedating antidepressant, is frequently prescribed due to its low cost and lack of controlled substance scheduling. It lacks strong trial data for insomnia at the doses commonly used (25 to 100 mg), and anticholinergic side effects can be problematic in older patients [5].

For patients who have not responded to or cannot tolerate GABAergic hypnotics, DORAs like lemborexant represent a mechanistically distinct alternative with a favorable safety profile, especially regarding abuse potential and next-day impairment at the 5 mg dose.